Title : Beta-blocker efficacy for intra- and interdialytic hypertension patients: A systematic review and meta-analysis
Abstract:
Purpose:
Intradialytic hypertension affects 5–15% of hemodialysis patients, yet relevant studies are relatively scarce. It is also associated with higher interdialytic blood pressure. Beta-blockers can be preferred as antihypertensive drugs due to their superior blood pressure control, decreased risk of cardiovascular events, improved endothelial cell function, and decreased noradrenaline levels. Through this study, beta blocker antihypertensive effects in intra- and interdialytic hypertension were analyzed.
Methods:
Systematic review and meta-analysis were performed following PRISMA guidelines. We registered our PROSPERO protocol (Registration ID: CRD42023446184) and included relevant full-text clinical trials or RCTs from 2008 to 2023 with predetermined keywords and criteria from multiple databases including PUBMED, COCHRANE, SCOPUS, and citation searching. Seven eligible articles were included in this review study.
Results:
Four studies with 82 participants for intradialytic hypertension evaluation were included. Meta-analysis showed a decrease in SBP in intradialytic hypertensive patients after beta-blocker intervention, with a significant estimated mean difference of -15.19 mmHg (P<0.00001; 95% CI −19.47 to −10.91). Supporting previous data, SBP remains constant between pre- and post-dialysis with beta-blocker therapy, with an insignificant estimated mean difference of -2.72 mmHg (P=0.29; 95% CI -7.80 to 2.36). Whereas five studies with 142 participants were included for interdialytic hypertension evaluation. Meta-analysis shows a significant decrease in SBP before-to-after therapy, with an estimated mean difference of -10.92 (P<0.0001; 95% CI -16.33 to -5.51).
Conclusion:
Beta-blocker treatment resulted in significant reductions in post-hemodialysis systolic blood pressure among intra- and interdialytic hypertensive patients.
Keywords: beta-blocker, intradialytic hypertension, interdialytic hypertension, hemodialysis, meta-analysis
Audience Take Away:
- Intradialytic hypertension affects 5–15% of hemodialysis patients, yet relevant studies are relatively scarce
- Beta-blockers can be preferred as antihypertensive drugs due to their superior blood pressure control, decreased risk of cardiovascular events, improved endothelial cell function, and decreased noradrenaline levels
- This is the first systematic review and meta-analysis on this topic, and further research is still needed
- Beta-blocker treatment resulted in significant reductions in post-hemodialysis systolic blood pressure among intra- and interdialytic hypertensive patients
